The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol


Taking the Shine Off Tivicay

December 19, 2016


Taking the Shine off Tivicay

In the three years since its Food and Drug Administration approval, Tivicay (dolutegravir) has become a mainstay of modern HIV treatment. It is one of the more powerful HIV drugs around, while having few problems with side effects, resistance or drug interactions.

So much so, that the scientists looking to simplify HIV treatment to a one- or two-drug regimen are focusing their efforts on Tivicay.

However, some recent, discouraging news about side effects may have taken the shine off Tivicay's reputation. It seems that more people than expected have complained of insomnia, dizziness and headache. How much of a concern is this?

Read on to find out more.

Get Started

Image credit: ViiV Healthcare.

Related Stories

An Overview of Dolutegravir
Dolutegravir and the Central Nervous System: A Top HIV Clinical Development of 2016 (on
2-Drug ART -- Paddling Against the 3-Drug Current: A Top HIV Clinical Development of 2016 (on
More News on Tivicay (Dolutegravir, DTG)

This article was provided by


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.